iSpecimen Inc.

What they do

iSpecimen operates a two-sided online marketplace that brings together healthcare providers holding human biofluids, tissues, and living cells with researchers in industry, academia, and government who need them. The platform ingests de-identified specimen and patient data from electronic medical records, laboratory information systems, and biobank inventory systems, harmonizes it, and lets researchers search, cart, quote, order, and track specimens. The company also handles marketing, sales, contracting, and compliance across both sides of the marketplace. When off-the-shelf specimens do not match researcher criteria, it distributes custom specimen collection requests across its provider network.

Revenue drivers

• Marketplace specimen procurement — Revenue comes from connecting researchers to biospecimens and associated data through the iSpecimen Marketplace, which the company describes as single-source access to millions of biospecimens across its provider network.
• Custom specimen collection — Researchers can request quotes for specimens not currently available, and those custom requests are distributed across the network of biospecimen providers, generating procurement revenue.
• Data and workflow services — The platform harmonizes de-identified specimen and patient data and orchestrates the bioprocurement workflow from request to fulfillment for providers and researchers.

Recent performance

Annual revenue declined from $11.1M in 2021 to $9.3M in 2024, then fell sharply to $1.9M in 2025. The company reported net losses every year, including $12.5M in 2024 and $10.5M in 2025, with an accumulated deficit of $82,350,149 as of December 31, 2025. Recent quarterly revenue was $156,009 for 2026-03-31 and $151,940 for 2026-06-30, following $106,592 in 2025-09-30 and $51,761 in 2025-12-31. At 2026-06-30, total assets were $7.4M, total liabilities $5.7M, shareholder equity $1.7M, and cash and equivalents $4.4M. Management concluded disclosure controls and procedures were not effective as of June 30, 2026 due to a material weakness in sales tax documentation, calculation, collection, reporting, and remittance.

Strategy

iSpecimen's stated mission is to accelerate life science research with a global marketplace platform connecting researchers to subjects, specimens, and associated data. The company continues to invest in the iSpecimen Marketplace, which it describes as an 'Amazon-like' platform for biospecimens, and to expand its network of healthcare provider organizations that supply specimens. It handles marketing, sales, contracting, and compliance across both sides of the marketplace to reduce friction in a fragmented procurement process. Management has been remediating a sales tax-related material weakness since the second quarter of fiscal 2023, with remediation ongoing as of the latest 10-Q. The company expects to cease qualifying as an emerging growth company on December 31, 2026 and to prepare for compliance with non-emerging growth company requirements beginning with its Form 10-K for the year ending December 31, 2026.

Risks

• Going concern — The company's audited financial statements include an explanatory paragraph expressing substantial doubt about its ability to continue as a going concern.
• Persistent losses — iSpecimen has incurred losses since its 2009 inception, reported net losses of $10,487,532 in 2025 and $12,497,805 in 2024, and had an accumulated deficit of $82,350,149 as of December 31, 2025.
• Revenue collapse — Annual revenue fell from $9.3M in 2024 to $1.9M in 2025, and recent quarterly revenue has remained at roughly $0.1M to $0.2M.
• Material weakness in controls — Management concluded disclosure controls and procedures were not effective as of June 30, 2026 because the company did not maintain adequate controls over customer tax-exempt status documentation and sales tax calculation, collection, reporting, and remittance.

Outlook

Management expects the company to remain an emerging growth company until December 31, 2026, when it will lose that status by passage of time under the JOBS Act. It expects to incur losses for the foreseeable future and to continue investing in business growth. The company continues efforts to remediate its sales tax-related material weakness, which began in the second quarter of fiscal 2023 and was still ongoing as of the latest 10-Q filing.